Evaluation of dexmedetomidine withdrawal in critically ill adults

• Published in: Journal of critical care 2021-04, Vol.62, p.19-24
• Main Authors: Pathan, Sophia, Kaplan, Justin B., Adamczyk, Katarzyna, Chiu, Stephanie H., Shah, Chirag V.
• Format: Article
• Language: English
• Subjects: Adrenergic alpha-2 receptor agonists; Adrenergic receptors; Adults; Anesthesia; Blood pressure; Cardiac arrhythmia; Delirium; Dexmedetomidine; Drug abuse; FDA approval; Heart rate; Hospitals; Hypertension; Hypnotics and sedatives; Intensive care; Medical records; Patients; Pediatrics; Psychotropic drugs; Substance withdrawal syndrome; Vomiting; Weaning
• ISSN: 0883-9441; 1557-8615
• DOI: 10.1016/j.jcrc.2020.10.024

Dexmedetomidine (DEX) withdrawal syndrome has been reported in the pediatric population, but literature describing DEX withdrawal in critically ill adults is limited. The purpose of this study was to determine the incidence of DEX withdrawal in adult patients and to identify factors associated with DEX withdrawal syndrome. A retrospective chart review was performed in the adult intensive care units of two tertiary medical centers. Eligible patients were at least 18 years of age and received DEX for 24 h or more. Patients were excluded if they presented with a primary neurologic diagnosis, had a history of substance abuse, or received any other α2-agonists 24 h before discontinuation of DEX. The primary outcome was the percentage of patients who developed withdrawal as defined by the presence of two or more symptoms (tachycardia, hypertension, vomiting, agitation) within the 24 h following DEX discontinuation. Of the 165 patients included, 50 patients experienced withdrawal (30.3%), lasting a median of two days. The incidence of withdrawal was higher in surgical (40%) compared to medical (28%) or cardiac (32%) patients (p = 0.004). Median duration of infusion was 52.5 h (interquartile range [IQR], 37.8 to 102.8) in the withdrawal group and 52 h (IQR, 41 to 87) in the non-withdrawal group (p = 0.887). Median DEX dose was 0.56 μg/kg/h (IQR, 0.39 to 0.83) in the withdrawal group and 0.48 μg/kg/h (0.36 to 0.65) in the non-withdrawal group (p = 0.12). Weaning did not reduce the incidence of withdrawal as compared to abrupt discontinuation (p = 0.68). The withdrawal group was more likely to have concomitantly discontinued opioids (54% vs 12.2%) and benzodiazepines (36% vs 0%) at the time of DEX discontinuation compared to the non-withdrawal group (p = 0.004). Development of DEX-associated withdrawal occurred in approximately 30% of adult patients, comparable to rates reported in pediatric literature. There appeared to be no correlation between dose, exposure, and weaning in the occurrence of withdrawal, but concomitant discontinuation of opioids or benzodiazepines as well as ICU admission type could highlight cases requiring closer monitoring. •Dexmedetomidine withdrawal syndrome includes symptoms of hypertension, tachycardia, agitation, nausea, and vomiting•Dexmedetomidine withdrawal after infusions of at least 24 h occurred in 30% of adult patients, comparable to pediatric rates•Concomitant discontinuation of opioids or benzodiazepines with dexmedetomidine may